Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

73 results about "Fat solubility" patented technology

Apigenin polylactic acid sustained release microsphere and preparation method thereof

ActiveCN103585113AOvercome water solubilityOvercome poor fat solubilityOrganic active ingredientsNervous disorderSolubilityBiocompatibility Testing
The invention discloses an apigenin polylactic acid sustained release microsphere and a preparation method of the apigenin polylactic acid sustained release microsphere. The preparation method comprises the following steps: dissolving hydroxyl-terminated racemic polylactic acid and soybean lecithin in an organic solvent; stirring the liquid, and slowly adding the apigenin mixed liquid subjected to ultrasonic treatment in an emulsifier aqueous solution to be emulsified; reducing the pressure, removing the solvent with steam, concentrating the volume; centrifuging at high speed, washing and drying the obtained mixed liquid to prepare the polylactic acid entrapped apigenin acid sustained release microsphere, wherein the microsphere particle size is 1-5 microns, the drug loading ratio is larger than 25%, the encapsulation efficiency is larger than 79%, and the sustained release time is more than 550 hours. According to the polylactic acid with good biocompatibility and biodegradability is taken as a clad material to prepare the apigenin polylactic acid sustained release microsphere, so that the microsphere is uniform in shape, smooth and adhesion-free on the surface, uniformly distributed in the particle size, and good in slow-release effect, can keep continuous release time in vitro 550 h above, conquers the defects that the drug is poor in water solubility and fat solubility, improves the oral administration availability, prolongs the drug action time and improves the drug therapeutic effect.
Owner:TAIYUAN UNIV OF TECH

Application of lipid-modified substance of chlorogenic acid and derivative thereof

The invention provides a lipid-modified substance of chlorogenic acid and a derivative thereof, and a preparation and purification method of the lipid-modified substance, wherein the lipid-modified substance includes the chlorogenic acid or the derivative thereof and phosphoglyceride. A preparation process includes steps of performing constant-temperature magnetic stirring reflux for a certain time to the chlorogenic acid or the derivative thereof and the phosphoglyceride with an aprotic solvent and drying an obtained reaction liquid to obtain a crude product. A purification process includes the steps of re-dissolving the crude product with filtration to obtain a filtrate and then drying the filtrate. The lipid-modified substance of the chlorogenic acid and the derivative thereof is high in composition rate and can significantly improve the fat-solubility of the chlorogenic acid and the derivative thereof, so that a subsequent preparation is convenient to process and shape. The lipid-modified substance can be used as an intermediate for preparing a lipidosome, nano particles, polymer micelles or a dendritic polymer and the like nano drug-delivery systems and micro emulsion, self-micro emulsion and the like micron drug-delivery systems, thereby enhancing in-vivo absorption of the chlorogenic acid and the derivative thereof and further increasing the bioavailability of the medicines in a preparation.
Owner:任静 +1

Thickened oil cold-water-injected fat-soluble dissolving nano oil-displacing agent as well as preparation method and application of nano oil-displacing agent

The invention discloses a thickened oil cold-water-injected fat-soluble dissolving nano oil-displacing agent HCD that comprises the following components in percentage by weight: 10-50% of ester compound, 5-30% of alcohol compound, 0-20% of amine compound or ether compound, 0-35% of sodium salt or ammonium salt, 0-20% of wetting agent, 0-20% of aldehyde compound, 0-20% of biosurfactant and 0-20% ofacidic substance. The invention further discloses a preparation method of the HCD and application of the HCD in oil field exploitation and rapid pipeline petroleum transportation. The HCD prepared bythe invention has the characteristics of strong fat solubility, water solubility, viscosity reduction, through-seam throat expansion, weak oil wetness, low tension, high oil displacement efficiency,safety and environmental protection; according to the invention, the oil displacing agent enters the nanometer gaps of the thickened oil; paraffin, asphalt and colloid are dissolved in a non-polar fat-soluble manner, the thickened oil is thinned by rapid viscosity reduction, the production is easy, the pipeline transportation is easy, and the low-cost and high-benefit large-scale industrial production of naphthenic thickened oil, super thickened oil and other thickened oil is realized.
Owner:CHENGDU NENGSHENGCAI SCI & TECH DEV CO LTD +1

Self-emulsifier containing breviscapine phosphatidylcholine complex, and preparation method and use thereof

InactiveCN103169657AHigh drug loadingSolve the problem of poor fat solubilityPowder deliveryOrganic active ingredientsOral medicationBioavailability
The invention discloses a self-emulsifier containing a breviscapine phosphatidylcholine complex, and a preparation method and a use thereof. The self-emulsifier comprises the following components, by mass, 0.1-16% of breviscapine, 0.1-32% of phosphatidylcholine, 20-70% of an oily phase, 10-50% of a surfactant, and 0-40% of a cosurfactant. An insoluble dug breviscapine is processed to prepare a breviscapine phosphatidylcholine complex, and the breviscapine phosphatidylcholine complex is treated as an intermediate carrier to prepare the self-emulsifier containing the breviscapine phosphatidylcholine complex. The breviscapine phosphatidylcholine complex can effectively solve a bad fat solubility problem of breviscapine and substantially improve the drug loading capability of the self-emulsifier; and the self-emulsifier can increase the dissolution rate of breviscapine, promote breviscapine to penetrate epithelial cells, promote the lymphatic transport of drugs to a certain degree, reduce the hepatic first pass metabolism of the drugs and improve the oral bioavailability of breviscapine. Oral administration tests of rats show that the self-emulsifier containing the breviscapine phosphatidylcholine complex can substantially improve the absorption of breviscapine and improve the oral bioavailability of breviscapine.
Owner:HUAZHONG UNIV OF SCI & TECH

Ferulic acid and phospholipid complex and application thereof to preparation of skin-whitening cosmetics

The invention discloses a ferulic acid and phospholipid complex and application thereof to preparation of skin-whitening cosmetics. The ferulic acid and phospholipid complex is obtained after ferulic acid and phospholipid are heated, stirred and compounded in a non-protonic solvent and the non-protonic solvent is removed. The invention also provides the skin-whitening cosmetics containing the ferulic acid and phospholipid complex. The cosmetics include skin oil, emulsion and cream with the skin whitening effect. According to the ferulic acid and phospholipid complex, ferulic acid and phospholipid are compounded, so that physicochemical properties of ferulic acid are changed, fat solubility, stability and water dispersibility of the complex are enhanced, the transmembrane transport performance of the complex is improved, and then the bioavailability of the complex is increased. After 30 female volunteers at the age of 25-45 use the skin-whitening and skin-caring emulsion containing the ferulic acid and phospholipid complex for 30 days, the melanin content of their faces is lowered obviously, the brightness of their skin is increased, the MI value, L* value and ITA degree value of their skin are remarkably different from original values (P<0.05), and it is indicated that the skin-whitening emulsion has a good human body skin whitening effect.
Owner:BEIJING TECHNOLOGY AND BUSINESS UNIVERSITY

Application of polygonin atomizing agent as asthma-treating medicine

The invention discloses an application of a polygonin atomizing agent as asthma-treating medicine. Each 1000 ml of polygonin spraying agent comprises 1 g of polygonin, 50 ml of propylene glycol, 1 g of sodium pyrosulfite, and the balance of water. Polygonin is prepared in the atomizing agent for the first time in the invention, and thus, the curative effect of asthma treatment is greatly increased through an administration method of atomizing inhalation. The molecular mass of polygonin is small, and the polygonin has the characteristics of fat solubility and no taste; the polygonin has certain solubility in airway secretion fluid or alveolar fluid, can be quickly absorbed through the membrane of an epithelial cell so as to arrive at a target cell and exert the efficacy for relieving asthma and diminishing inflammation, and is suitably prepared into the atomizing agent without adding more additives; asthma is treated through the administration method of atomizing inhalation, and the curative effect of the polygonin atomizing agent is superior to a peroral dosage form of polygonin. Compared with other various dosage forms, the polygonin atomizing agent effectively saves dosage and manufacturing cost, reduces bad effect on patients, and is beneficial to environment protection.
Owner:江庆澜

Synthesis method of nicotinamide modified polyaspartic acid derivative

The invention relates to a synthesis method of a nicotinamide modified polyaspartic acid derivative. The nicotinamide modified polyaspartic acid derivative is synthesized by using L-aspartic acid as araw material, phosphoric acid as a catalyst, and nicotinamide as a modifier. The synthesis method mainly comprises the following steps: stirring L-aspartic acid and phosphoric acid, heating to obtainpolysuccinimide (PSI), adding nicotinamide into a PSI reaction kettle, reacting to enable PSI to be subjected to ring-opening grafting to achieve the purpose of modification, and finally adding an alkali solution for hydrolysis to obtain a nicotinamide grafted and modified polyaspartic acid derivative sodium salt aqueous solution. The synthesis method disclosed by the invention is simple and easyto operate, and the grafting modification step and the polymerization step are coupled in one reactor, so that the process steps can be simplified, and the polymerization degree and the grafting ratecan be regulated and controlled. The synthesized nicotinamide modified polyaspartic acid derivative has good hydrophilicity, fat solubility and chelation, has the effects of moisturizing, removing freckles, whitening, improving skin quality, removing heavy metals and the like, and is a multifunctional and high-value polyaspartic acid derivative product.
Owner:苏州美瑞姿生物科技有限公司

Quercetin derivative chemically modified by dodecanoyl chloride and synthesis method thereof

The invention discloses a quercetin derivative chemically modified by dodecanoyl chloride and a synthesis method thereof, belonging to the field of pharmaceutical synthesis. The method comprises the following steps of: adding raw materials namely quercetin and dodecanoyl chloride into a solvent, adding a proper amount of catalyst and acidity regulator, reacting for 8-10 hours under the condition of ice water bath to room temperature, adjusting the pH value to 6-7 with acid after the reaction is finished, adding water, extracting with ethyl acetate, separating liquid, and continuously extracting a water layer with ethyl acetate for 2-3 times. Combine ethyl acetate layers, adde water absorbing agent, overnight, suction filtering, distil to remove ethyl acetate to obtain crude product, purifying with 200-300 mesh silica gel column chromatography, preparing liquid phase, and purifying again to obtain quercetin derivative with high purity. The quercetin derivative obtained by the inventioncarries out chemical modification on natural quercetin, and is favorable for improving water solubility and fat solubility and improving bioavailability through substitution reaction at the 4'-OH hydroxyl position. The quercetin derivative can be used for treating diseases such as hypertension, myocardial ischemia and cancer.
Owner:ZHEJIANG UNIV OF TECH +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products